Segall Bryant & Hamill, LLC Alkermes Plc. Transaction History
Segall Bryant & Hamill, LLC
- $7.16 Billion
- Q3 2024
A detailed history of Segall Bryant & Hamill, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 1,183,100 shares of ALKS stock, worth $37.3 Million. This represents 0.46% of its overall portfolio holdings.
Number of Shares
1,183,100
Previous 1,220,935
3.1%
Holding current value
$37.3 Million
Previous $29.4 Million
12.54%
% of portfolio
0.46%
Previous 0.53%
Shares
19 transactions
Others Institutions Holding ALKS
# of Institutions
359Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$918 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$598 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$410 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$399 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$290 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.18B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...